Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel™)
Status:
Active, not recruiting
Trial end date:
2024-02-01
Target enrollment:
Participant gender:
Summary
This is a randomized phase III open-label, multicenter trial evaluating standard induction
therapy (daunorubicin [DNR] and cytarabine [Ara-C]) and consolidation therapy (high-dose
cytarabine [HDAC]) with or without dasatinib in adult patients with newly diagnosed CBF-AML